Some biomarkers become so accepted that they become part of routine data collection; for example, anti-citrullinated peptide antibodies (ACPA) detected by anti-cyclic citrullinated peptide (anti-CCP) antibodies are now routinely tested because they define a subset of cases with RA with a more severe disease course [2]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.